Market closedNon-fractional
Xencor/XNCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Xencor
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Ticker
XNCR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Pasadena, United States
Employees
280
Website
www.xencor.com
Xencor Metrics
BasicAdvanced
$1.3B
Market cap
-
P/E ratio
-$2.19
EPS
0.77
Beta
-
Dividend rate
Price and volume
Market cap
$1.3B
Beta
0.77
Financial strength
Current ratio
7.081
Quick ratio
6.87
Long term debt to equity
12.953
Total debt to equity
14.592
Management effectiveness
Return on assets (TTM)
-9.96%
Return on equity (TTM)
-20.71%
Valuation
Price to revenue (TTM)
7.982
Price to book
2.13
Price to tangible book (TTM)
2.2
Price to free cash flow (TTM)
26.235
Growth
Revenue change (TTM)
65.41%
Earnings per share change (TTM)
-6.54%
3-year revenue growth (CAGR)
9.28%
3-year earnings per share growth (CAGR)
25.48%
What the Analysts think about Xencor
Analyst Ratings
Majority rating from 13 analysts.
Xencor Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$13M
-71.30%
Net income
-$68M
256.02%
Profit margin
-531.25%
1,140.66%
Xencor Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.37
-$0.40
-$0.31
-$1.11
-
Expected
-$0.80
-$0.73
-$0.09
-$0.79
-$0.86
Surprise
-53.59%
-44.94%
250.43%
40.12%
-
Xencor News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xencor stock?
Xencor (XNCR) has a market cap of $1.3B as of July 27, 2024.
What is the P/E ratio for Xencor stock?
The price to earnings (P/E) ratio for Xencor (XNCR) stock is 0 as of July 27, 2024.
Does Xencor stock pay dividends?
No, Xencor (XNCR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Xencor dividend payment date?
Xencor (XNCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Xencor?
Xencor (XNCR) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Xencor stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.